Illumina scoops up Oxford Nanopore's core technology for a steal

Illumina (Nasdaq: ILMN) recently signed an exclusive worldwide agreement with Oxford Nanopore Technologies (see the December 8, 2008 LRBJ) providing Illumina with the rights to Oxford Nanopore’s BASE (Bayley Sequencing) technology for the marketing, sales, distribution, and servicing of BASE in both...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research


Company Profile | June 17, 2021

Molzym was founded by Michael Lorenz in 2003 and was acquired by Gradian Diagnostics in December 2019 The company's core technology is a culture‑free enrichment method for bacterial and fungal DNA, which it sells as a kit or different components of the kit as needed by the end user It also ... Not part of subscription

OriCiro Genomics raises ¥1 billion (~$9 million) Series B for DNA technology

News Commentary | July 29, 2021

The Japanese startup develops tools for the synthesis and amplification of DNA. The company claims improvements over the traditional PCR and E. coli cloning techniques through the use of an isothermal and cell‑free process. OriCiro plans to use the funds in order to expand its manufacturing ... Not part of subscription

PacBio acquires Omniome in deal worth $800 million, expanding its DNA sequencing capabilities

News Commentary | August 02, 2021

PacBio specializes in long‑read DNA sequencing, which provides insights on genomic variants including immunology, rare diseases, and microbiology. The company seeks to complement its service by integrating Omniome's short‑read sequencing (SRS) platform, which can be utilized for cancer screening, ... Not part of subscription